Significance of changes in tumor markers in patients treated with durvalumab plus tremelimumab combination therapy as a surrogate marker for tumor response to unresectable hepatocellular carcinoma
Shinsuke Uchikawa,
Tomokazu Kawaoka,
Serami Murakami
et al.
Abstract:AimWhen evaluating response to immune checkpoint inhibitor therapy, the tumor sometimes initially swells before shrinking and ultimately responding, also called pseudo‐progression. In this study, we analyzed whether tumor markers were useful for reflecting the treatment response.MethodsThirty‐three patients who were treated with durvalumab plus tremelimumab combination therapy (Dur + Tre) were enrolled. Their functional reserve was Child–Pugh grade A. Their tumor markers α‐fetoprotein (AFP), des‐γ‐carboxy prot… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.